Skip to content
Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc.

HRMY

Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases.

Market cap
$2.08B+2.3%
Revenue$899.1M+20.7%
Net income$145.6M-4.7%
EPS (diluted)$2.49-5.0%
Trailing twelve months · change vs. prior year

Earnings

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$249.0M
EPS estimate$0.97

Financials

Q1 2026

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%

Valuation & ratios

Valuation

See full
Market cap$2.08B+2.3%
Enterprise value$1.66B-1.2%
P/E14.3×+3.0×
P/S2.3×-0.3×

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Segments

By segment

See full
Rare Neurological Diseases$215.4M+16.6%

Competitors

Profile

Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases. The company's core value proposition centers on its sleep/wake franchise, led by a first-in-class therapy that enhances histamine signaling in the brain without being classified as a controlled substance. Harmony is actively expanding its portfolio into rare epilepsy and neurobehavioral disorders through strategic acquisitions and licensing agreements.

Competitive position

Harmony holds a unique market position with the only FDA-approved narcolepsy treatment that is not a DEA-scheduled controlled substance.

GeographiesUnited States, Latin America
Customer segmentsSpecialty pharmacies, Healthcare providers, Patients with rare neurological diseases
Business modelR&D-based drug development, Specialty pharmaceutical commercialization
SuppliersThird-party API manufacturers, Contract manufacturing organizations (CMOs), Clinical research organizations (CROs), Licensing partners for intellectual property
CustomersCaremark LLC, Accredo Health Group, Inc., PANTHERx Specialty Pharmacy LLC, Specialty distributors
Listed2020
Employees246.0
CEOJeffrey Dayno
FilingsSEC EDGAR

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s market cap?
Harmony Biosciences Holdings, Inc. (HRMY) has a market capitalization of $2.1B and trades on NASDAQ.
What is Harmony Biosciences Holdings, Inc.'s revenue and profitability?
Harmony Biosciences Holdings, Inc. generated $899.1M in trailing twelve-month revenue with net income of $145.6M, representing a net margin of 16.2%. Gross margin stands at 76.5%. These figures are based on the Q1 2026 filing.
Who are Harmony Biosciences Holdings, Inc.'s competitors?
Harmony Biosciences Holdings, Inc.'s key competitors include Jazz Pharmaceuticals, Axsome Therapeutics, Amneal Pharmaceuticals, and others. These companies compete in similar markets and product categories.
Who does Harmony Biosciences Holdings, Inc. partner with?
Harmony Biosciences Holdings, Inc.'s notable partners include Bioprojet Société Civile de Recherche, CiRC Biosciences, Inc., Teijin Pharma, and others.
What subsidiaries does Harmony Biosciences Holdings, Inc. have?
Harmony Biosciences Holdings, Inc.'s subsidiaries include Harmony Biosciences, LLC, Harmony Biosciences Management, Inc., Epygenix Therapeutics, Inc., and others.
Where is Harmony Biosciences Holdings, Inc. headquartered?
Harmony Biosciences Holdings, Inc. is headquartered in United States of America and employs approximately 246 people. It has been publicly traded since 2020.